XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.1
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Changes in Fair Value of Level 3 Liabilities
The following table sets forth a summary of changes in the fair value of Level 3 liabilities, the warrants issued in connection with the Company's merger with Flex Pharma in 2019, which are measured at fair value on a recurring basis for the three months ended March 31, 2021:
DescriptionBalance at December 31, 2020Change in Fair ValueBalance at March 31, 2021
Warrant liability$59,211 $46,054 $105,265